FEATURES OF L-ARGININE-CITRULLINE CYCLE FUNCTIONING IN PATIENTS WITH MULTIPLE MYELOMA WITH CONCOMITANT CORONARY HEART DISEASE
DOI:
https://doi.org/10.15407/exp-oncology.2025.01.076Keywords:
nitric oxide, NO synthase, L-arginine, lipid peroxidation, multiple myeloma, coronary artery disease, arginaseAbstract
Background. Disorders of the L-arginine-citrulline cycle affect the functioning of the cardiovascular system. Cancerinduced augmentation of arginase activity stimulates the biotransformation of L-arginine to form polyamines, which causes NO deficiency and increases the risk of endothelial dysfunction in the category of high-risk patients for developing cytostatic-induced cardiotoxicity. The aim was to investigate features of L-arginine-citrulline cycle functioning in patients with multiple myeloma (MM) and concomitant coronary artery disease (CAD) during chemotherapy (CT). Materials and Methods. 42 patients with MM progression were examined and divided into 2 groups: group І (n = 20) — patients without CAD and group II (n = 22) — patients with CAD. The concentrations of L-arginine and citrulline and the activity of arginase in the blood serum of the patients were measured before and after the 1st and 5th courses of chemotherapy. Results. Before chemotherapy, in patients of both groups, the blood serum level of L-arginine decreased, while the activity of arginase and the level of citrulline increased compared to healthy individuals. In patients of group II, the level of citrulline was higher than in patients of group I. After the 5th course of chemotherapy, L-arginine content in patients of both groups increased and citrulline levels decreased compared to the initial examination. Conclusions. The progression of MM was accompanied by a decrease in the blood serum content of L-arginine along with an increase in the arginase activity in the blood serum compared to practically healthy individuals. An increase in the cumulative dose of cytostatics during CT in the MM patients with concomitant CAD led to a decrease in the content of L-arginine in the blood serum with a simultaneous increase in the content of citrulline compared to corresponding levels in MM patients without concomitant CAD.
References
Molek P, Zmudzki P, Wlodarczyk A, et al. The shifted balance of arginine metabolites in acute myocardial infarction patients and its clinical relevance. Sci Rep. 2021;11(1):83. https://doi.org/10.1038/s41598-020-80230-3
Skrypnyk I, Maslova G, Lymanets T, et al. L-arginine is an effective medication for prevention of endothelial dys- function, a predictor of anthracycline cardiotoxicity in patients with acute leukemia. Exp Oncol. 2017;39(4):308-311. https://doi.org/10.31768/2312-8852.2017.39(4):308-311
Hranyk V. Metabolism of L-arginine (review). Khym Farm Zh. 2003;37(3):3-20. https://doi.org/10.30906/0023-1134- 2003-37-3-3-20 (in Russian).
Pedrazini MC, Martinez EF, dos Santos VAB, Groppo FC. L-arginine: its role in human physiology, in some diseases and mainly in viral multiplication as a narrative literature review. Futur J Pharm Sci. 2024;10(1):99. https://doi. org/10.1186/s43094-024-00673-7
Jahani-Asl A, Bonni A. iNOS: a potential therapeutic target for malignant glioma. Curr Mol Med. 2013;13(8):1241- 1249. https://doi.org/10.2174/1566524011313080002
Kondo S, Toyokuni S, Tsuruyama T, et al. Peroxynitrite-mediated stress is associated with proliferation of hu- man metastatic colorectal carcinoma in the liver. Cancer Lett. 2002;179(1):87-93. https://doi.org/10.1016/s0304- 3835(01)00859-x
Kagoura M, Matsui C, Toyoda M, et al. Immunohistochemical study of inducible nitric oxide synthase in skin can- cers. J Cutan Pathol. 2001;28(9):476-481. https://doi.org/10.1034/j.1600-0560.2001.028009476.x
Skrypnyk I, Maslova GS, Lymanets TV, et al. The overweight and obesity role in the occurrence of chemotherapy- induced hepatotoxic reactions in patients with acute myeloid leukemia. Wiad Lek. 2022;75(6):1506-1511. https:// doi.org/10.36740/WLek202206114
Maxwell AJ, Cooke JP. Cardiovascular effects of L-arginine. Curr Opin Nephrol Hypertens. 1998;7(1):63-70. https:// doi.org/10.1097/00041552-199801000-00011
Kashfi K, Kannikal J, Nath N. Macrophage reprogramming and cancer therapeutics: Role of iNOS-derived NO.
Cells. 2021;10(11):3194. https://doi.org/10.3390/cells10113194
Zharynova V, Butynets Zh, Pavlenko L. Efficiency of using L-arginine in treatment of chronic cardiaс failure in aged patients with coronary heart disease. Simeina Medytsyna. 2014(5):47-52 (in Russian).
Skrypnyk I, Maslova G, Lymanets T, et al. How to improve quality of life in patients with acute leukemia and comor- bid ischemic heart disease treated with anthracycline-based induction chemotherapy. Exp Oncol. 2019;41(4):353- 356. https://doi.org/10.32471/exp-oncology.2312-8852.vol-41-no-4.13906
Matsuzaki H, Hata H, Sonoki T, et al. Serum amino acid disturbance in multiple myeloma with hyperammonemia.
Int J Hematol. 1995;61(3):131-137. https://doi.org/10.1016/0925-5710(95)00359-z
Trudu M, Oliva L, Orfanelli U, et al. Preclinical evidence of a direct pro-survival role of arginine deprivation in multiple myeloma. Front Oncol. 2022;12:968208. https://doi.org/10.3389/fonc.2022.968208
Ministry of Health of Ukraine. Unified clinical protocol for primary, secondary (specialized), and tertiary (highly specialized) medical care: multiple myeloma. Kyiv: Ministry of Health of Ukraine; 2015 Nov 2. Available from: https://www.dec.gov.ua/mtd/mnozhynna-miyeloma/
Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagno- sis, treatment and follow-up. Ann Oncol. 2021;32(3):309-322. https://doi.org/10.1016/j.annonc.2020.11.014
Ministry of Health of Ukraine. Unified clinical protocol for primary, secondary (specialized), and tertiary (highly specialized) medical care: stable ischemic heart disease. Kyiv: Ministry of Health of Ukraine; 2021. Available from: https://www.dec.gov.ua/mtd/home/
Van Pilsum JF. Determination of creatinine and related guanidinium compounds. Meth Biochem Anal. 1959:193- 215. https://doi.org/10.1002/9780470110232.ch6
Khramov VA, Listopad GG. Modification of Chinard method for measuring ornitine for quantification of blood serum arginase. Lab Delo. 1973;10:591-592 (in Russian).
Boyde TR, Rahmatullah M. Optimization of conditions for the colorimetric determination of citrulline, using di- acetyl monoxime. Anal Biochem. 1980;107(2):424-431. https://doi.org/10.1016/0003-2697(80)90404-2
Katz DL, Jekel JF, Elmore JG, Wild DMG, Lucan SC. Jekel’s Epidemiology, Biostatistics, Preventive Medicine, and Public Health. Philadelphia, PA: Saunders, an imprint of Elsevier Inc. Philadelphia, PA; 2014.
Wang X, Xiang H, Toyoshima Y, et al. Arginase-1 inhibition reduces migration ability and metastatic colonization of colon cancer cells. Cancer Metab. 2023;11(1):1. https://doi.org/10.1186/s40170-022-00301-z
Peyraud F, Guégan JP, Bodet D, et al. Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors. Ann Oncol. 2022;33(10):1041-1051. https://doi.org/10.1016/j.annonc.2022.07.001
Oktem G, Bilir A, Selvi N, et al. Chemotherapy influences inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) activity on 3D breast cancer cell line. Oncol Res. 2006;16(4):195-203. https://doi. org/10.3727/000000006783981107
Sherif IO, Sabry D, Abdel-Aziz A, et al. The role of mesenchymal stem cells in chemotherapy-induced gonadotoxi- city. Stem Cell Res Ther. 2018;9(1):196. https://doi.org/10.1186/s13287-018-0946-6
de Belder AJ, Radomski MW, Why HJ, et al. Nitric oxide synthase activities in human myocardium. Lancet. 1993;341(8837):84-85. https://doi.org/10.1016/0140-6736(93)92559-c
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
